Modus Therapeutics Holding AB (FRA:99Z) EPS (Basic) : €-0.04 (TTM As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Modus Therapeutics Holding AB EPS (Basic)?

Modus Therapeutics Holding AB's basic earnings per share (Basic EPS) for the three months ended in Sep. 2024 was €-0.01. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Sep. 2024 was €-0.04.

Modus Therapeutics Holding AB's EPS (Diluted) for the three months ended in Sep. 2024 was €-0.01. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was €-0.04.

Modus Therapeutics Holding AB's EPS without NRI for the three months ended in Sep. 2024 was €-0.01. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2024 was -0.04.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Modus Therapeutics Holding AB EPS (Basic) Historical Data

The historical data trend for Modus Therapeutics Holding AB's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Modus Therapeutics Holding AB EPS (Basic) Chart

Modus Therapeutics Holding AB Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

-0.26

-0.04

-0.16

-0.10

-0.09

Modus Therapeutics Holding AB Quarterly Data
	Dec19	Mar20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EPS (Basic)	Get a 7-Day Free Trial														-0.02	-0.01	-0.01	-0.01	-0.01

Modus Therapeutics Holding AB EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Modus Therapeutics Holding AB's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-1.6	-	0)	/	17.745
	=	-0.09

Modus Therapeutics Holding AB's Basic EPS for the quarter that ended in Sep. 2024 is calculated as

Basic EPS (Q: Sep. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-0.263	-	0)	/	35.939
	=	-0.01

EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.04

Modus Therapeutics Holding AB (FRA:99Z) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Modus Therapeutics Holding AB EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Modus Therapeutics Holding AB's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Modus Therapeutics Holding AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Modus Therapeutics Holding AB (FRA:99Z) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

MODTX:Sweden

Address

Olof Palmes gata 29 IV, Stockholm, SWE, 111 22

Website

https://www.modustx.com

Modus Therapeutics Holding AB is a Swedish clinical biotechnology company developing a treatment for sepsis, endotoxemia, severe malaria, and other disorders with severe systemic inflammation as well as states of anemia, related to chronic inflammation such as kidney diseases through its patented polysaccharide sevuparin. The drug candidate sevuparin has the opportunity to benefit patients and save large healthcare costs.

Modus Therapeutics Holding AB Headlines

No Headlines